retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity

retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity First-in-Class 'Triple-G'! Retatrutide, a first-in Retatrutide Obesity Treatment Shows Promising

Name: retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity First-in-Class 'Triple-G'! Retatrutide, a first-in Retatrutide Obesity Treatment Shows Promising
Brand: coasta-de-azur.fr
SKU: 68316068791
Price: 28.31 USD
Availability: InStock
Rating: 4.0243 (6 reviews)

SKU: 68316068791

4.0

EUR28.31 EUR67.31

Pay in 4 interest-free payments of $7.08 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 10 - Aug 15

Description

Retatrutide is a triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors

Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D

STEPS AWAY FROM A YOUNGER

Should retatrutide receive a positive regulatory decision, it would then be subject to a health technology appraisal (HTA) by NICE (National Institute for Health and Care Excellence) to determine its clinical and cost-effectiveness relative to existing treatments